Bottom line
Is IBB a good fund? The bottom line
IBB is an actively managed technology sector ETF from iShares.
It charges 0.44% — about $44 a year on every $10,000 invested, cheaper than 86% of technology sector funds we track.
It returned +28.0% over one year, +2.5% a year over five years, +4.4% a year over ten (as of Dec 31, 2025, per its prospectus).
With $5.9 billion in net assets and 254 holdings, its largest position is BlackRock Funds III (13.2%) and the top 10 make up 59% of the portfolio.
The closest lower-cost alternative we found is IBBQ (0.19%, 56% top-holdings overlap).
What stands out
- Low cost: cheaper than 86% of technology sector peers
- Broadly diversified (254 holdings)
What to watch
- 5-year return in the bottom quarter of its category
- Concentrated: top 10 holdings are 59% of assets
Updated Nov 19, 2026
What IBB invests in
The iShares Biotechnology ETF (the Fund ) seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector.
The Fund seeks to track the investment results of the NYSE Biotechnology Index (the Underlying Index ), which measures the performance of U.S.-listed securities of companies that are classified according to the ICE Uniform Sector Classification schema within the Biotechnology Sub-Industry Group (as determined by ICE Data Indices, LLC or its affiliates (collectively Index Provider or IDI )) and that also meet other eligibility criteria determined by the Index Provider, including minimum market capitalization and liquidity requirements. Companies classified within the Biotechnology Sub-Industry Group include those companies that are engaged in the research and development of therapeutic treatments but that are not focused on the commercialization and mass production of pharmaceutical drugs. The Biotechnology Sub-Industry Group also includes those companies that are engaged in the…
From the fund's prospectus (filed Jul 27, 2026).
IBB performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| IBB | +28.0% | +2.5% | +4.4% |
| Technology Sector median | +24.0% | +10.0% | +16.7% |
Source: Fund prospectus, as of Dec 31, 2025
What IBB costs
On a $10,000 investment, IBB's 0.44% expense ratio costs about $44 a year. The prospectus estimates $555 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.
IBB top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | BlackRock Funds III | 13.18% |
| 2 | Vertex Pharmaceuticals, Inc. | 7.66% |
| 3 | Gilead Sciences, Inc. | 7.52% |
| 4 | Amgen, Inc. | 7.50% |
| 5 | Regeneron Pharmaceuticals, Inc. | 5.70% |
| 6 | Alnylam Pharmaceuticals, Inc. | 5.68% |
| 7 | IQVIA Holdings, Inc. | 3.18% |
| 8 | Argenx SE | 3.15% |
| 9 | Insmed, Inc. | 2.95% |
| 10 | Mettler-Toledo International, Inc. | 2.49% |
Source: SEC Form N-PORT, period ended Sep 30, 2025
The top 10 make up 59% of the fund. See all top 25 holdings and asset mix →